Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Biotechs Get Share Of £1bn Coronavirus Support Fund

Payments Must Not Be Delayed, Says BIA

Executive Summary

Small-to-medium non-profit making UK biotechs will be supported via loans and grants, but government unmoved by Tax Credits suggestion for whole sector.

You may also be interested in...



UK Biotechs Seek Government Help As Economic ‘Heart Attack’ Threatens Sector

Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel